I'm sure @
Jonathan Edwards will chime in at some point.
From what I know about Rituxan and RA and a recent visit with my rheumatologist @ Ucla, every RA patients responds differently and not every RA patients is a responder to Rituxan. Also Rituxan is usually not the first line of treatment for RA.
@
IreneF the protocol and timing of the infusions is certainly something that Fluge and Mella have been working very hard to figure out and make as right as possible for the most of their ME patients, even more so for the phase III.
That's why we need clinical studies like the one in the UK @ UCL, studies that replicate intelligently and in connection with the original norwegian. It might seem a waste of time and money, but it's the only way we can go to advance the science, the understanding and translate that into a treatment.